VKTX
Viking Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$28.99
−1.26%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$29.57
From 52W high−31.19%
Volume2.65M
Market cap$3.38B
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$29.57
From 52W high
−31.19%
Volume
2.65M
Market cap
$3.38B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−5.4x
P/E (TTM)
—
RSI (14)
29.5
MomentumView details →
1D Return
−1.26%
YTD Return
−18.90%
SummaryUpdated Jun 1, 2026
Viking Therapeutics, Inc. (NASDAQ:VKTX) is a clinical-stage biopharmaceutical company founded in 2012 and headquartered in San Diego, California. The company went public in 2015 and focuses on developing novel therapies for metabolic and endocrine disorders. Viking has emerged as a significant player in the obesity and metabolic disease treatment space, with multiple drug candidates in various stages of clinical development targeting conditions such as obesity, non-alcoholic steatohepatitis (NASH), and rare metabolic disorders.
Similar companies
Latest newsMore news →
Viking Therapeutics, Inc. (VKTX) shares fell 1.44% to close at $29.52 on the latest trading day.4d agoViking Therapeutics, Inc. (VKTX) shares closed at $32.13, down 1.74% from the previous trading session.10d agoViking Therapeutics announced its financial results for the second quarter and six months ended June 30, 2026.53d ago